GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (BUE:JNJ) » Definitions » Retained Earnings

Johnson & Johnson (BUE:JNJ) Retained Earnings : ARS55,537,323 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Johnson & Johnson Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Johnson & Johnson's retained earnings for the quarter that ended in Dec. 2023 was ARS55,537,323 Mil.

Johnson & Johnson's quarterly retained earnings increased from Jun. 2023 (ARS31,051,440 Mil) to Sep. 2023 (ARS53,379,975 Mil) and increased from Sep. 2023 (ARS53,379,975 Mil) to Dec. 2023 (ARS55,537,323 Mil).

Johnson & Johnson's annual retained earnings increased from Dec. 2021 (ARS12,427,829 Mil) to Dec. 2022 (ARS21,517,039 Mil) and increased from Dec. 2022 (ARS21,517,039 Mil) to Dec. 2023 (ARS55,537,323 Mil).


Johnson & Johnson Retained Earnings Historical Data

The historical data trend for Johnson & Johnson's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Retained Earnings Chart

Johnson & Johnson Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,614,486.79 9,268,367.87 12,427,829.14 21,517,038.66 55,537,323.05

Johnson & Johnson Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24,606,433.47 31,051,439.75 53,379,974.67 55,537,323.05 -

Johnson & Johnson Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Johnson & Johnson  (BUE:JNJ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Johnson & Johnson (BUE:JNJ) Business Description

Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.